The dual-blockade therapy combining durvalumab with tremelimumab (anti-CTLA-4 mAb) is currently being investigated for R/M HNSCC (NCT02551159, NCT02369874, and NCT02319044). Here, CTLA4 is linked to head and neck squamous cell carcinoma.